{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:41:56Z","timestamp":1794271316777,"version":"4.9.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":98,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T23:10:41Z","timestamp":1756509041000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategies"],"prefix":"10.1053","volume":"62","author":[{"given":"Marion","family":"Subklewe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rutella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.08.003_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/hematology.2023000455","article-title":"Novel immunotherapies in the treatment of AML: is there hope?","volume":"2023","author":"Subklewe","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.08.003_bib0007","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.08.003_bib0008","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Gill","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.003_bib0009","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/2643-3230.BCD-24-0140","article-title":"SOCS1 Protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity","volume":"6","author":"Tin","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33\u202f\u00d7\u202fCD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.08.003_bib0011","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.003_bib0012","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood-2024-199211","article-title":"MP0533 (CD33 x CD123 x CD70 x CD3), a tetra-specific CD3-engaging darpin for the treatment of patients with relapsed\/refractory AML or MDS\/AML: results of an ongoing phase 1\/2a study","volume":"144","author":"Jongen-Lavrencic","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0013","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.08.003_bib0014","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial CART therapy in AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo AML: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.003_bib0016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.003_bib0017","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory AML: a phase \u00bd study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Onocl"},{"key":"10.1053\/j.seminhematol.2025.08.003_bib0018","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2022-168877","article-title":"Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy Unicar-T-CD123 in relapsed\/refractory AML","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.08.003_bib0019","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.003_bib0020","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1182\/blood-2022-160209","article-title":"Preclinical characterization of NGM936, a novel bispecific T cell engager targeting ILT3 for the treatment of AML with monocytic differentiation","volume":"140","author":"Lin","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100110","article-title":"Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Hutchings","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.08.003_bib0022","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.003_bib0023","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0024","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.14104","article-title":"Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human AML","volume":"112","author":"Wang","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40364-022-00390-4","article-title":"Integrated multiomic approach for identification of novel immunotherapeutic targets in AML","volume":"10","author":"K\u00f6hnke","year":"2022","journal-title":"Biomark Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.08.003_bib0026","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.08.003_bib0027","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment- free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.003_bib0028","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41375-025-02528-3","article-title":"Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia","volume":"39","author":"Abedin","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.08.003_bib0029","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1158\/1535-7163.MCT-23-0720","article-title":"Targeting CD33+ acute myeloid leukemia with GLK-33, a Lintuzumab-auristatin conjugate with a wide therapeutic window","volume":"23","author":"Satomaa","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.003_bib0030","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","article-title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","volume":"8","author":"Lane","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.003_bib0031","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0032","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","article-title":"Unveiling the potential of CLL-1: a promising target for AML therapy","volume":"13","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Biomark Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2024013590","article-title":"CD37 in acute myeloid leukemia: a novel surface target for drug delivery","volume":"9","author":"Jeremy","year":"2025","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-206538","article-title":"IO-202, a novel anti-LILRB4 antibody, with Azacitidine for hypomethylating agent-naive chronic myelomonocytic leukemia: phase 1b expansion cohort results","author":"Mannis","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.08.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169519","article-title":"LAIR-1 agonism as a therapy for acute myeloid leukemia","volume":"133","author":"Lovewell","year":"2023","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.08.003_bib0036","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-19-1093","article-title":"Characterization of a novel FLT3 BiTE molecule for the treatment of AML","volume":"19","author":"Brauchle","year":"2020","journal-title":"Mol Cancer Therapy"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.003_bib0037","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41375-024-02510-5","article-title":"Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates","volume":"39","author":"Able","year":"2025","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.08.003_bib0038","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.08.003_bib0039","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/10428194.2022.2148212","article-title":"A randomized phase II\/III study of \u201cnovel therapeutics\u201d versus azacitidine in newly diagnosed patients with AML, high risk MDS, or CMML, age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOGS1612","volume":"64","author":"Assouline","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101247","article-title":"Immune checkpoint inhibitors in AML","volume":"34","author":"Daver","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_bib0041","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk MDS (STIMULUS-MDS1): a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8_Supplement_2","key":"10.1053\/j.seminhematol.2025.08.003_bib0042","doi-asserted-by":"crossref","first-page":"CT225","DOI":"10.1158\/1538-7445.AM2025-CT225","volume":"85","author":"Buecklein","year":"2025","journal-title":"Cancer Res"},{"issue":"31","key":"10.1053\/j.seminhematol.2025.08.003_bib0043","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody Magrolimab combined with Azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.08.003_bib0044","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice in untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.08.003_bib0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"ENHANCE-3: venetoclax and azacitidine plus magrolimab or placebo in untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.08.003_bib0046","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.003_bib0047","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory AML","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.08.003_bib0048","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory AML","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.003_bib0049","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood-2024-199211","article-title":"MP0533 (CD33 x CD123 x CD70 x CD3), a tetra-specific CD3-engaging darpin for the treatment of patients with relapsed\/refractory AML or MDS\/AML: results of an ongoing phase 1\/2a study","volume":"144","author":"Jongen-Lavrencic","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.08.003_bib0050","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.2020010477","article-title":"Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody","volume":"138","author":"Augsberger","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.003_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101135","article-title":"Development of a gene edited next-generation hematopoietic cell transplant to enable AML treatment by solving off-tumor toxicity","volume":"31","author":"Lydeard","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.08.003_bib0052","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.003_sbref0054","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1053\/j.seminhematol.2025.08.003_bib0054","doi-asserted-by":"crossref","unstructured":"Vadakekolathu J and Rutella S. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia blood. 2024; 143(26):2689-2700. doi: 10.1182\/blood.2023019961.","DOI":"10.1182\/blood.2023019961"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.08.003_bib0055","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knau","year":"2018","journal-title":"JCI insight"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.08.003_bib0056","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41375-024-02387-4","article-title":"Evolution of T-cell fitness through AML progression: enahnced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse","volume":"38","author":"Kazerani","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.003_bib0057","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41375-023-02127-0","article-title":"Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of AML: a preclinical assessment","volume":"38","author":"H\u00e4nel","year":"2024","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:27:27Z","timestamp":1765632447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000368"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}